Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).

Sechaud, Romain; Sinclair, Karen; Grosch, Kai; Ouatas, Taoufik; Pathak, Dhrubajyoti

Sechaud, Romain; Sinclair, Karen; Grosch, Kai; Ouatas, Taoufik; Pathak, Dhrubajyoti.

Affiliation

Sechaud R; Novartis Pharma AG, CH-4002, Basel, Switzerland. romain.sechaud@novartis.com.
Sinclair K; Novartis Pharma AG, CH-4002, Basel, Switzerland.
Grosch K; Novartis Pharma AG, CH-4002, Basel, Switzerland.
Ouatas T; Novartis Pharma AG, CH-4002, Basel, Switzerland.
Pathak D; Novartis Pharma AG, CH-4002, Basel, Switzerland.

Cancer Chemother Pharmacol ; 90(1): 19-27, 2022 07.

Article in En | MEDLINE | ID: mdl-35751657

Subject(s)

Cytochrome P-450 CYP3A Inhibitors; Leukemia, Myeloid, Acute; Cytochrome P-450 CYP3A/genetics; Cytochrome P-450 CYP3A Inhibitors/pharmacology; Cytochrome P-450 CYP3A Inhibitors/therapeutic use; Drug Interactions; Humans; Leukemia, Myeloid, Acute/drug therapy; Leukemia, Myeloid, Acute/genetics; Mutation; Protein Kinase Inhibitors; Staurosporine/adverse effects; Staurosporine/analogs & derivatives; fms-Like Tyrosine Kinase 3/genetics

Key words

Acute myeloid leukemia; CYP3A4; Drugdrug interaction; Midostaurin; Post hoc analysis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Cytochrome P-450 CYP3A Inhibitors Type of study: Clinical_trials Limits: Humans Language: En Journal: Cancer Chemother Pharmacol Year: 2022 Type: Article Affiliation country: Switzerland

Fulltext

XML

PubMed Links

Search on Google